Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $15.05 USD
Change Today 0.00 / 0.00%
Volume 0.0
MTZXF On Other Exchanges
Symbol
Exchange
Berlin
Tokyo
OTC US
OTC US
OTC US
As of 8:10 PM 06/18/15 All times are local (Market data is delayed by at least 15 minutes).

mitsubishi tanabe pharma (MTZXF) Snapshot

Open
$15.05
Previous Close
$15.05
Day High
$15.05
Day Low
$15.05
52 Week High
03/12/15 - $17.42
52 Week Low
07/10/14 - $14.45
Market Cap
8.4B
Average Volume 10 Days
20.0
EPS TTM
--
Shares Outstanding
561.4M
EX-Date
09/28/15
P/E TM
--
Dividend
$44.14
Dividend Yield
2.44%
Current Stock Chart for MITSUBISHI TANABE PHARMA (MTZXF)

Related News

No related news articles were found.

mitsubishi tanabe pharma (MTZXF) Related Businessweek News

No Related Businessweek News Found

mitsubishi tanabe pharma (MTZXF) Details

Mitsubishi Tanabe Pharma Corporation manufactures and sells pharmaceuticals in Japan and internationally. The company offers autoimmune drugs, including Remicade agent for rheumatoid arthritis and Crohn’s disease, Bechet’s disease with refractory uveoretinitis, psoriasis, ankylosing spondylitis, and ulcerative colitis; and Simponi agent for rheumatoid arthritis. It also provides drugs for diabetes and kidney diseases, such as Kremezin agent for chronic renal failure; and Tanatril agent for hypertension and diabetic nephropathy with type I diabetes mellitus, etc. In addition, the company offers drugs for central nervous system diseases comprising Radicut, a cerebral neuroprotectant; Ceredist agent for spinocerebellar degeneration; Depas, an anti-anxiety agent; and Lexapro, an anti-depressant agent. Further, it provides Maintate agent for treatment of hypertension, angina pectoris, ventricular extrasystole, chronic heart failure, and atrial fibrillation; Talion agent for allergic disorders; Urso agent for the improvement of hepatic, biliary, and digestive function; Anplag, an anti-platelet agent; and Herbesser, an agent for angina pectoris and hypertension. Additionally, the company offers vaccines, such as TETRABIK, a combined vaccine for diphtheria, pertussis, tetanus, and poliomyelitis; and influenza. It also provides over-the-counter products, including herbal and digestive medicines, as well as oral solutions for tonic and nutritional supplement; oral agent for allergic rhinitis; and products for the treatment of skin conditions and recurrent vaginal candidiasis. The company also offers pharmaceutical information and real estate management services; sells generic pharmaceuticals, chemicals, etc.; invests in bio-ventures; and is involved in distribution and warehouse operations. The company was founded in 1678 and is headquartered in Osaka, Japan. Mitsubishi Tanabe Pharma Corporation is a subsidiary of Mitsubishi Chemical Holdings Corporation.

8,457 Employees
Last Reported Date: 06/19/15
Founded in 1678

mitsubishi tanabe pharma (MTZXF) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

mitsubishi tanabe pharma (MTZXF) Key Developments

Mitsubishi Tanabe Pharma Corporation, Q4 2015 Earnings Call, May 11, 2015

Mitsubishi Tanabe Pharma Corporation, Q4 2015 Earnings Call, May 11, 2015

Mitsubishi Tanabe Pharma Corporation Announces Consolidated Earnings Results for the Year Ended March 31, 2015; Provides Earnings Guidance for the First Half and Full Year Ending March 31, 2016

Mitsubishi Tanabe Pharma Corporation announced consolidated earnings results for the year ended March 31, 2015. For the year, the company reported net sales of ¥415,124 million against ¥412,675 million a year ago. Operating income was ¥67,133 million against ¥59,119 million a year ago. Ordinary income was ¥67,654 million against ¥61,873 million a year ago. Net income was ¥39,502 million against ¥45,393 million a year ago. Net income per share was ¥70.41 against ¥80.92 a year ago. Return on equity was 5.1% against 6.0% a year ago. Net assets per share were ¥1,406.41 as on March 31, 2015 against ¥1,365.52 as on March 31, 2014. Cash flows from operating activities were ¥68,167 million against ¥69,896 million a year ago. Income before income taxes and minority interests was ¥62,677 million against ¥72,441 million a year ago. Purchase of property, plant and equipment was ¥12,976 million compared to ¥12,302 million for the same period a year ago. Purchase of intangible fixed assets was ¥1,503 million compared to ¥2,038 million for the same period a year ago. The company provided earnings guidance for first half for the fiscal year ending March 31, 2016. For the first half, the company expects to report net sales of ¥191,500 million, operating income of ¥28,000 million, ordinary income of ¥28,000 million and net income of ¥19,000 million or ¥33.87 per share. The company provided earnings guidance for full year for the fiscal year ending March 31, 2016. For the full year, the company expects to report net sales of ¥396,000 million, operating income of ¥67,500 million, ordinary income of ¥67,000 million and net income of ¥40,500 million or ¥72.19 per share.

Mitsubishi Tanabe Pharma Corporation Announces Dividend of Retained Earnings, Payable on June 22, 2015

Mitsubishi Tanabe Pharma Corporation announced Retained Earnings dividend per share of ¥22.00. Effective date is June 22, 2015 and record date is March 31, 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MTZXF:US $15.05 USD 0.00

MTZXF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MTZXF.
View Industry Companies
 

Industry Analysis

MTZXF

Industry Average

Valuation MTZXF Industry Range
Price/Earnings 25.6x
Price/Sales 2.4x
Price/Book 1.3x
Price/Cash Flow 19.4x
TEV/Sales 1.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MITSUBISHI TANABE PHARMA, please visit www.mt-pharma.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.